Price T Rowe Associates Inc. MD Purchases Shares of 13,561 Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Price T Rowe Associates Inc. MD purchased a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,561 shares of the company’s stock, valued at approximately $47,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TRVI. Oppenheimer & Co. Inc. bought a new position in Trevi Therapeutics in the 1st quarter worth $208,000. Propel Bio Management LLC purchased a new position in shares of Trevi Therapeutics in the first quarter valued at about $897,000. Opaleye Management Inc. boosted its stake in shares of Trevi Therapeutics by 48.6% in the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after acquiring an additional 829,100 shares during the period. Vanguard Group Inc. boosted its stake in shares of Trevi Therapeutics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after acquiring an additional 60,249 shares during the period. Finally, Frazier Life Sciences Management L.P. grew its position in shares of Trevi Therapeutics by 7.3% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after purchasing an additional 500,000 shares in the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Up 0.7 %

Shares of Trevi Therapeutics stock opened at $2.77 on Monday. Trevi Therapeutics, Inc. has a twelve month low of $0.97 and a twelve month high of $4.00. The business has a 50-day moving average price of $2.79 and a 200-day moving average price of $2.76. The firm has a market cap of $195.10 million, a price-to-earnings ratio of -8.15 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter last year, the firm posted ($0.07) earnings per share. On average, equities analysts expect that Trevi Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the transaction, the insider now owns 220,315 shares in the company, valued at $608,069.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 76,478 shares of company stock worth $199,349. Insiders own 24.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday, May 8th. Rodman & Renshaw assumed coverage on shares of Trevi Therapeutics in a research report on Thursday, June 13th. They set a “buy” rating and a $7.00 price objective on the stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.